To verify the role of FGF2 in bevacizumab resistance, tumour (Y-MESO-14 cells)-bearing mice were treated with a FGFR inhibitor (BGJ-398)21 in combination with bevacizumab. The gene discussed is FGF2; the disease is neoplasm.